# Liver-Sparing Total Body Irradiation Using Helical Tomotherapy for Relapsed Pre-B-cell Acute Lymphoblastic Leukemia

**Authors:** Romy J Megahed, Gary D Lewis, Somayeh Gholami, April Wurtz, Santanu Samanta, Mausam Patel

PMC · DOI: 10.7759/cureus.100343 · 2025-12-29

## TL;DR

This paper presents a first case of liver-sparing total body irradiation using helical tomotherapy for a leukemia patient with pre-existing liver disease.

## Contribution

The first reported use of helical tomotherapy to perform liver-sparing TBI in a patient with prior liver disease.

## Key findings

- Tomotherapy delivered 12 Gy to the body in eight fractions while keeping the mean liver dose at 5.98 Gy.
- The liver constraint of a mean dose under 9 Gy was successfully met.
- This case shows the feasibility of liver-sparing TBI in patients with pre-existing liver conditions.

## Abstract

Liver toxicity is an uncommon but reported complication of total body irradiation (TBI). The risk of this complication may be magnified in patients with previous hepatic parenchymal disease. In this context, to the best of our knowledge, we present the first case of liver-sparing TBI using helical tomotherapy in a patient with pre-existing liver disease.

In this case, we discuss a 23-year-old male with relapsed precursor B-cell acute lymphoblastic leukemia (pre-B-ALL) who received myeloablative TBI. Tomotherapy allowed us to treat the entire body to 12 Gy in eight fractions, while achieving a mean liver dose of 5.98 Gy, meeting the targeted liver constraint of a mean dose less than 9 Gy. This case demonstrates the feasibility of liver-sparing TBI.

## Full-text entities

- **Diseases:** hepatic parenchymal disease (MESH:D002543), pre-B-ALL (MESH:D015452), liver disease (MESH:D008107), Liver toxicity (MESH:D056486), Acute Lymphoblastic Leukemia (MESH:D054198)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12850990/full.md

---
Source: https://tomesphere.com/paper/PMC12850990